Esperion Therapeutics Inc is a United States-based biopharmaceutical company focused on the research, development and commercialization of therapies for the treatment of patients with elevated levels of low-density lipoprotein cholesterol (LDL-C) and other cardiometabolic risk factors. The Company has focused its initial drug discovery and development activities on drugs to treat acute and chronic cardiovascular and metabolic diseases. Esperion Therapeutics Inc is also engaged in the identification and clinical development of synthetic HDL Therapies.